NEPHROTIC SYNDROME: MINIMAL CHANGE DISEASE
Abstract
Heavy Proteinuria. Edema. Hyperproteinemia. andHyperlipidemia characterize the nephrotic syndrome(NS).CLASSIFICATIONThe syndrome can be divided into congenital, primary(idiopathic), and secondary types.1. Minimal-change disease. (75%)2. Mesangio- proliferative. (<5%)3. Focal-segmental lesion. (10%)4. Membranous nephropathy. (<5%)5. Membrano proliferative glomerulonephritis.Type I, II and III (10%).ETIOLOGY90% of the children have some form of the idiopathicnephrotic syndrome. Minimal-change disease is foundin approximately 75%. Where as in 10% of thechildren with Nephrosis, the nephrotic syndrome islargely mediated by some form of glomerulonephritis,membranous and Membrano-proliferative are mostcommon. It is widely accepted that minimal changenephrotic syndrome (MCNS) is the most commoncause of nephritis in children. Recent studies show thatthe incidence of Focal Segmental Glomerulosclerosis(FSGS) in children with idiopathic nephroticsyndrome has increased recently.29References
Behrman, Kliegman and Jenson, Textbook of pediatrics; 2000;
th edition; 1592*96
Freehally J. Kendell NP, Swift PGF. Walls J. High incidence
of* minimal change nephrotic syndrome in Asians. Arch Dis
Child 1985; 60: 1018-20.
Nash MA, Edelman CM, Bernstein J, Bernstein J. Barnett HL.
The nephrotic syndrome. In: Edelman CM, ed. Pediatr kidney
diseases. 2 - edition. Boston: Little Brown, 1992; 1274-66.
Levine M, Gascoine P, Turner MW, Barratt TM. A highly
cationic protein in plasma and urine of children with steroid
responsive nephrotic syndrome. Kidney Int. 1989; 36; 867- 77.
Schnaper HW. A regulatory system for soluble immune
response suppressor production in steroid responsive
nephrotic syndrome. Kidney Int. 1990; 38; 151-9.
Arbeitsgemeinschaft Fur Padiatrische Nephrologic. Shop
versus standard prednisone therapy for initial treatment of
idiopathic nephrotic syndrome in children. Lancet 1988; l:
-3.
Arbeitsgemeinschaft Fur Padiatrische Nephrologic. Alternate
day versus intermittent prednisone in frequently relapsing
nephrotic syndrome. Lancet 1979; 401-3.
Choonara 1A, Haney D, Meadow SR, Low dose prednisolone
in nephrotic syndrome. Arch Dis Child 1989. 64; 610-2.
Brodent J. Conventional therapy for idiopathic nephrotic
syndrome. Clin Nephor 1991; 35 (Suppl I); S8-15.
Lewis MA, Baildom EM, Davis N, Houston IB, Post lethwaite
RJ. Nephrotic syndrome; from toddlers to twenties. Lancet
, 255-9.
Koskimies O. Long term outlook of primary nephrotic
syndrome. Arch Dis Child 1982; 57; 544 —8.
International study of kidney diseases in children. Early
identification of frequent relapses among children with
minimal change nephrotic syndrome. J Pediatr 1982; 101: 514-
Wingen AM, Muller-Wiefel DE, Scharer K. Spontaneous
remission in frequently relapsing and steroid dependent
idiopathic nephrotic syndrome. Clin Nephrol 1985; 23: 35-8.
International study of kidney diseases in children. Nephrotic
syndrome in children. A randomized trial comparing two
regimens in steroid responsive patients who relapse early. J
Pediatr 1979: 95: 239-43.
Brodehl J. Nephrotic syndrome in children. Diagnosis and
treatment. World pediatrics and child health care 1986; 1:9-18
Trumpeter RS, Loyd BS, Hicks J. White RHR, Cameron GS.
Long-term outcome for children with minimal change
nephrotic syndrome. Lancet 1985; 368-70.
Moxon ER. Should Children with Nephrotic Syndrome be
immunized Against Pneumococcal Infection? Pediatr Nephrol
; 5:283.
Hober PF, Gonda S, Barthels M, Krohin HP, Brodeh IJ.
Thromboembolic complications in children with nephrotic
syndrome. Acta Paediatr Scand 1986; 75:804-10.
International study of kidney disease in children. Prospective
controlled trial of cyclophosphamide in children with
nephrotic syndrome. Lancet 1974; ii: 423-7.
Grape WE, Makker SP, Ingelfingcr JR. Chlorambucil
treatment of frequently relapsing nephrotic syndrome. N Engl
J Med 1976: 295: 746-9.
British Association for pediatrics nephrology Levamisole for
corticosteroid dependent nephrotic syndrome in childhood.
Lancet 1991:337: 1555-7.
Niaudet P. Broyer M, Habib R. Treatment of idiopathic
nephrotic syndrome with cyclosporine A in children. Clin
Nephrol 1991; 35 (Suppl I): S3126-6.
Tejani A, Suthanthiran M. Pomrantz A. A randomized
controlled trial of low dose prednisolone and cyclosporine
versus high dose prednisolone in nephrotic syndrome of
childhood. Nephron 1991; 59: 96-9.
Trompeter, RS. Steroid resistant nephrotic syndrome: A
review* of the treatment of focal segmental
glomerulosclerosis in children. In: Recent Advances In
Pediatric Nephrology. Murakami K. Kitagawa T, Yabuta K,
Sakai, (Eds), Excerpta Medica, Amsterdam, 1987; 363-371.
Mendoza SA, Reznik M, Griswold WR, et al. Treatment of
steroid resistant focal segmental glomerulosclerosis with pure
methylprednisolone and alkylating agents. Pediatr Nephrol
; 4: 303.
Tune BM, Kirpekar R, Sibley RF, et al. Intravenous
methylprednisolone and oral alkylating agent therapy of
prednisone resistant pediatric focal glomerulosclerosis: A long
term follow up. Clin Nephrol 1995; 43:84.
Broyer M, Mcziane A, Kleinknecht C, Niaudet P. nitrogen
mustard therapy in idiopathic nephrotic syndrome of
childhood. Int J Pediatr Nephrol 1985; 6: 29.
A report of the international study of kidney diseases in
children. The primary nephrotic syndrome in children;
Identification of patients with minimal change nephrotic
syndrome: J Pediatr 1981; 98:561.
Bonilia-Felix M. Parra C, Dajani T, Ferris M, Swinford RD,
Portman RJ. Changing patterns in the histopathology of
idiopathic nephrotic syndrome in children. Verani Kidney Int
May; 55(5): 1885-90
Prasher PK, Varma P and Baliga KV. Efficacy of enalapril in
the treatment of steroid resistant idiopathic nephritic
syndrome. J Assoc. Physicians India 1999 Feb; 47(2): 180-2.
Nikolov DG, Pandeva SM, Kumchev EP, Tsekov VD, Tilkian
EE, Manev EK, Tsvetkova ZS, Anavi BL and Dimitrakov.
Treatment of immune nephropathies with high doses of
immunoglobulins. Folia Med. (Plovdiv) 2000; 42(1): 10-3.
Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N,
Ebihara I and Koide H. The urinary podocytes as a marker for
the differential diagnosis of idiopathic focal
glomerulosclerosis and minimal-change nephrotic syndrome.
Am J Nephrol 2000 May-Jun; 20(3): 175-9
Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi
A, Sangalli F and Remuzzi G. ACE inhibition improves
glomerular size selectivity in-patients with idiopathic
membranous nephropathy and persistent nephritic syndrome.
Am J Kidney Dis 2000 Mar; 35(3): 381-91.
Bagga A, Hari P and Srivastava RN. Prolonged versus
standard prednisolone therapy for initial episode of nephritic
syndrome. Pediatr Nephrol 1999 Nov; 13(9): 824-7.
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
